Liver International,
Journal Year:
2022,
Volume and Issue:
42(4), P. 742 - 748
Published: Feb. 19, 2022
Polarizing
opinions
have
recently
arisen
in
hepatology
on
the
name
and
redefinition
of
fatty
liver
disease
associated
with
metabolic
dysfunction.
In
spite
growing
robust
evidence
superior
utility
term
(dysfunction)
(MAFLD)
definition
for
clinical
academic
practice,
controversy
abounds.
It
should
therefore
come,
as
no
surprise
that
most
common
arguments
used
contrarian
op-eds
is
there
are
consensus
any
change.
this
context,
we
suggest
discourse
an
accurate
understanding
what
scientific
means,
various
methods
achieving
consensus,
well
other
alternative
models
reaching
agreement
pivotal
field.
opinion
piece,
provide
overview
these
aspects
it
applies
to
case
disease.
We
a
change
from
non-alcoholic
(NAFLD)
MAFLD
has
already
been
achieved.
believe
time
come
redirecting
stakeholder
focus
energy
capitalizing
momentum
generated
by
debate
improve
lives
people
at
its
centre,
our
patients.
The Journal of Clinical Endocrinology & Metabolism,
Journal Year:
2022,
Volume and Issue:
107(9), P. 2691 - 2700
Published: May 19, 2022
Abstract
Background
and
Aims
Metabolic-associated
fatty
liver
disease
(MAFLD)
was
proposed
as
a
better
definition
of
nonalcoholic
(NAFLD)
to
encompass
the
metabolic
dysregulation
associated
with
NAFLD.
This
redefinition
challenges
our
understanding
disease.
Hence,
this
study
sought
conduct
an
updated
analysis
prevalence,
clinical
characteristics,
factors
MAFLD,
further
sensitivity
done
based
on
lean
nonobese
MAFLD
individuals.
Methods
Medline
Embase
databases
were
searched
include
articles
MAFLD.
Meta-analysis
proportions
conducted
using
generalized
linear
mix
model.
Associating
evaluated
in
conventional
pairwise
meta-analysis
Results
From
pooled
involving
3
320
108
individuals,
overall
prevalence
38.77%
(95%
CI
32.94%
44.95%);
5.37%
4.36%
6.59%)
29.78%
26.06%
33.79%)
respectively,
had
Metabolic
complications
such
hypertension
[odds
ratio
(OR)
2.63,
95%
1.85
3.74,
P
<
0.0001
OR
2.03;
1.74
2.38,
0.0001,
respectively]
diabetes
(OR
3.80,
2.65
5.43,
3.46,
2.81
4.27,
respectively)
found
significant
associating
Conclusions
supports
previous
studies
reporting
affect
more
than
third
global
population.
While
exploration
pathogenic
basis
without
is
required,
emphasis
management
concomitant
can
improve
multidisciplinary
efforts
managing
complex
HepatoBiliary Surgery and Nutrition,
Journal Year:
2023,
Volume and Issue:
12(3), P. 386 - 403
Published: Feb. 24, 2023
With
the
rising
global
prevalence
of
fatty
liver
disease
related
to
metabolic
dysfunction,
association
this
common
condition
with
chronic
kidney
(CKD)
has
become
increasingly
evident.
In
2020,
more
inclusive
term
dysfunction-associated
(MAFLD)
was
proposed
replace
non-alcoholic
(NAFLD).
The
observed
between
MAFLD
and
CKD
our
understanding
that
can
be
a
consequence
underlying
dysfunction
support
notion
individuals
are
at
higher
risk
having
developing
compared
those
without
MAFLD.
However,
date,
there
is
no
appropriate
guidance
on
in
Furthermore,
been
little
attention
paid
link
Nephrology
community.Using
Delphi-based
approach,
multidisciplinary
panel
50
international
experts
from
26
countries
reached
consensus
some
open
research
questions
regarding
CKD.This
statement
provided
epidemiology,
mechanisms,
management
treatment
CKD,
as
well
relationship
severity
which
establish
framework
for
early
prevention
these
two
interconnected
diseases.
Hepatology Research,
Journal Year:
2021,
Volume and Issue:
52(5), P. 422 - 432
Published: Sept. 2, 2021
Recently,
international
expert
panels
have
proposed
a
new
definition
of
fatty
liver:
metabolic
dysfunction-associated
liver
disease
(MAFLD).
MAFLD
is
not
just
simple
renaming
non-alcoholic
(NAFLD).
The
unique
feature
the
inclusion
dysfunctions,
which
are
high-risk
factors
for
events.
In
addition,
independent
alcohol
intake
and
co-existing
causes
disease.
This
concept
may
widespread
impact
on
patients,
medical
doctors,
staff,
various
stakeholders
regarding
liver.
Thus,
renovate
clinical
practice
awareness
this
review,
we
introduce
rationale
MAFLD.
We
further
describe
representative
cases
showing
how
diagnostic
processes
differ
between
NAFLD.
also
summarize
recent
studies
comparing
with
NAFLD
discuss
trials,
Japanese
populations,
awareness.
Clinical and Molecular Hepatology,
Journal Year:
2021,
Volume and Issue:
27(2), P. 257 - 269
Published: March 22, 2021
There
is
some
dissatisfaction
with
the
term
“nonalcoholic
fatty
liver
disease
(NAFLD),”
which
overemphasizes
alcohol
and
underemphasizes
importance
of
metabolic
risk
factors
in
this
disease.
Recently,
a
consensus
recommended
“metabolic
(dysfunction)-associated
(MAFLD)”
as
more
appropriate
to
describe
diseases
(FLD)
associated
dysfunction.
During
definition
change
from
NAFLD
MAFLD,
subjects
FLD
abnormalities,
together
other
etiologies
such
alcohol,
virus,
or
medication
who
have
been
excluded
criteria,
were
added
MAFLD
while
but
without
abnormality,
included
criteria.
This
means
that
there
an
emphasis
on
dysfunction
may
underestimate
prognostic
value
hepatic
steatosis
itself,
whereas
criteria
might
better
identify
are
at
higher
cardiovascular
outcomes.
However,
non-metabolic
missed
diagnosis,
their
potential
can
be
cause
future
diseases.
Although
huge
controversies
remain,
review
focused
summarizing
recent
studies
compared
clinical
characteristics
between
MAFLD.
Clinical and Molecular Hepatology,
Journal Year:
2021,
Volume and Issue:
28(2), P. 150 - 163
Published: Nov. 10, 2021
Fatty
liver
is
now
a
major
cause
of
disease
in
the
Asia-Pacific
region.
Liver
diseases
this
region
have
distinctive
characteristics.
First,
fatty
frequently
observed
lean/normal-weight
individuals.
However,
there
no
standard
definition
unique
phenotype.
Second,
often
patients
with
concomitant
viral
hepatitis.
The
exclusion
hepatitis
from
non-alcoholic
limits
its
value
and
detracts
investigation
holistic
management
coexisting
Third,
liver-associated
hepatocellular
carcinoma
(HCC)
generally
categorized
as
non-B
non-C
HCC.
Fourth,
population
aging
rapidly,
it
imperative
to
develop
practicable,
low-intensity
exercise
program
for
elderly
patients.
Fifth,
most
nonspecialized
healthcare
professionals
still
lack
an
awareness
significance
both
terms
intrahepatic
extrahepatic
cancer.
Recently,
international
expert
panel
proposed
new
liver:
metabolic
dysfunction-associated
(MAFLD).
One
feature
MAFLD
that
dysfunction
prerequisite
diagnosis.
Pertinent
regional
issues,
also
provides
diagnostic
criteria
Furthermore,
independent
any
disease,
including
Therefore,
may
be
more
suitable
In
review,
we
introduce
characteristics
discuss
advantages
improving
clinical
practice
Current Opinion in Gastroenterology,
Journal Year:
2022,
Volume and Issue:
38(3), P. 251 - 260
Published: Feb. 9, 2022
Purpose
of
review
In
2020,
a
novel
comprehensive
redefinition
fatty
liver
disease
was
proposed
by
an
international
panel
experts.
This
aims
to
explore
current
evidence
regarding
the
impact
this
new
definition
on
understanding
epidemiology,
pathogenesis,
diagnosis,
and
clinical
trials
for
disease.
Recent
findings
The
effectiveness
metabolic
dysfunction-associated
(MAFLD)
compared
existing
criteria
nonalcoholic
(NAFLD).
data
robustly
suggest
superior
utility
MAFLD
in
identifying
patients
at
high
risk
dysfunction,
hepatic
extra-hepatic
complications,
as
well
those
who
would
benefit
from
genetic
testing,
including
with
concomitant
diseases.
change
name
also
appears
have
improved
awareness
among
physicians.
Summary
transformation
NAFLD
represents
important
milestone,
which
indicates
significant
tangible
progress
towards
more
inclusive,
equitable,
patient-centred
approach
addressing
profound
challenges
Growing
has
illustrated
broader
specific
contexts
that
tremendous
potential
positively
influencing
diagnosis
treatment.
addition,
momentum
accompanying
included
widespread
public
attention
unique
burden
previously
underappreciated
